{"title":"在连续血糖测量中考虑低血糖治疗。","authors":"Elliott C Pryor, Anas El Fathi, Marc D Breton","doi":"10.1177/19322968251329952","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) is increasingly used in the management of diabetes, providing dense data for patients and clinical providers to review and identify patterns and trends in blood glucose. However, behavioral factors like hypoglycemia treatments (HTs) are not captured in CGM data. Hypoglycemia treatments, by definition, reduce the visibility (frequency and duration) of hypoglycemia exposure recorded by CGM, which can lead to errors in treatment management when relying solely on CGM metrics.</p><p><strong>Methods: </strong>We propose a method to incorporate HTs into CGM-based metrics and standardize hypoglycemia exposure quantification for a variety of HT behaviors; specifically (1) treatment proactiveness and (2) potential severity of the avoided hypoglycemia. In addition, we introduce an HT detector to identify instances of HT using in CGM data that otherwise lack HT documentation. We then use the HT-modified hypoglycemia metrics in a previously published run-to-run treatment adaptation system using CGM-based metrics.</p><p><strong>Results: </strong>Using in-silico data to correct time-below-range with HT, we reconstruct the avoided hypoglycemia exposure with high fidelity (<i>R</i><sup>2</sup> = .94). Our HT detector has an F1 score of 0.72 on clinical data with labeled HT. In the example run-to-run application, we reduce the average number of HT per day from 3.3 in the HT-unaware system to 1.6, while maintaining 84% time in 70 to 180 mg/dL.</p><p><strong>Conclusion: </strong>This new metric integrates HT behaviors into CGM-based analysis, offering a behavior-sensitive measure of hypoglycemia exposure for more robust T1D management. Our results show that HT can be seamlessly incorporated into existing CGM methods, enhancing treatment insights by accounting for HT variability.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968251329952"},"PeriodicalIF":4.1000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics.\",\"authors\":\"Elliott C Pryor, Anas El Fathi, Marc D Breton\",\"doi\":\"10.1177/19322968251329952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Continuous glucose monitoring (CGM) is increasingly used in the management of diabetes, providing dense data for patients and clinical providers to review and identify patterns and trends in blood glucose. However, behavioral factors like hypoglycemia treatments (HTs) are not captured in CGM data. Hypoglycemia treatments, by definition, reduce the visibility (frequency and duration) of hypoglycemia exposure recorded by CGM, which can lead to errors in treatment management when relying solely on CGM metrics.</p><p><strong>Methods: </strong>We propose a method to incorporate HTs into CGM-based metrics and standardize hypoglycemia exposure quantification for a variety of HT behaviors; specifically (1) treatment proactiveness and (2) potential severity of the avoided hypoglycemia. In addition, we introduce an HT detector to identify instances of HT using in CGM data that otherwise lack HT documentation. We then use the HT-modified hypoglycemia metrics in a previously published run-to-run treatment adaptation system using CGM-based metrics.</p><p><strong>Results: </strong>Using in-silico data to correct time-below-range with HT, we reconstruct the avoided hypoglycemia exposure with high fidelity (<i>R</i><sup>2</sup> = .94). Our HT detector has an F1 score of 0.72 on clinical data with labeled HT. In the example run-to-run application, we reduce the average number of HT per day from 3.3 in the HT-unaware system to 1.6, while maintaining 84% time in 70 to 180 mg/dL.</p><p><strong>Conclusion: </strong>This new metric integrates HT behaviors into CGM-based analysis, offering a behavior-sensitive measure of hypoglycemia exposure for more robust T1D management. Our results show that HT can be seamlessly incorporated into existing CGM methods, enhancing treatment insights by accounting for HT variability.</p>\",\"PeriodicalId\":15475,\"journal\":{\"name\":\"Journal of Diabetes Science and Technology\",\"volume\":\" \",\"pages\":\"19322968251329952\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes Science and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/19322968251329952\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968251329952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics.
Background: Continuous glucose monitoring (CGM) is increasingly used in the management of diabetes, providing dense data for patients and clinical providers to review and identify patterns and trends in blood glucose. However, behavioral factors like hypoglycemia treatments (HTs) are not captured in CGM data. Hypoglycemia treatments, by definition, reduce the visibility (frequency and duration) of hypoglycemia exposure recorded by CGM, which can lead to errors in treatment management when relying solely on CGM metrics.
Methods: We propose a method to incorporate HTs into CGM-based metrics and standardize hypoglycemia exposure quantification for a variety of HT behaviors; specifically (1) treatment proactiveness and (2) potential severity of the avoided hypoglycemia. In addition, we introduce an HT detector to identify instances of HT using in CGM data that otherwise lack HT documentation. We then use the HT-modified hypoglycemia metrics in a previously published run-to-run treatment adaptation system using CGM-based metrics.
Results: Using in-silico data to correct time-below-range with HT, we reconstruct the avoided hypoglycemia exposure with high fidelity (R2 = .94). Our HT detector has an F1 score of 0.72 on clinical data with labeled HT. In the example run-to-run application, we reduce the average number of HT per day from 3.3 in the HT-unaware system to 1.6, while maintaining 84% time in 70 to 180 mg/dL.
Conclusion: This new metric integrates HT behaviors into CGM-based analysis, offering a behavior-sensitive measure of hypoglycemia exposure for more robust T1D management. Our results show that HT can be seamlessly incorporated into existing CGM methods, enhancing treatment insights by accounting for HT variability.
期刊介绍:
The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.